The FDA has expanded approval of teplizumab-mzwv (Tzield, Sanofi) for use in children as young as 1 year of age who have early-stage type 1 diabetes (T1D). First approved in November 2022 for children ...

Hosted in partnership with the TMH Foundation, the camp includes IMAX films, robotics activities and lessons about how insulin pumps and continuous glucose monitors work.

NEW YORK, April 22, 2026 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision by the U.S. Food and ...

FDA expanded teplizumab-mzwv to stage 2 T1D in children ≥ 1 year, establishing earlier immunomodulatory intervention during the presymptomatic window rather than post–stage 3 management. PETITE-T1D ...

Children with well-regulated type 1 diabetes (T1D) showed early vascular changes, with increased intima thickness in radial and dorsal pedal arteries as opposed to healthy control individuals without ...

Increased interest in screening for the genetic risk of type 1 diabetes (T1D) has been driven by factors including the introduction of immune interventions. Saliva-based screening can be leveraged to ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic ...

Scientists uncover how exposure to a mother’s type 1 diabetes during pregnancy may epigenetically “reprogram” her child’s immune system, offering new clues to lifelong protection against the disease.

Sanofi SNY announced that the FDA has approved its type I diabetes (T1D) drug, Tzield (teplizumab), for a new indication under the accelerated pathway. The agency has cleared the therapy to delay the ...